Geneseeq and Zai Lab (ZLAB) Announce Strategic Collaboration to Advance Cancer Drug R&D
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Geneseeq and Zai Lab Announce Strategic Collaboration to Advance Cancer Drug R&D
October 13, 2021 10:00 AM EDTTORONTO, Oct. 13, 2021 /PRNewswire/ - Geneseeq Technology Inc. ("Geneseeq") and Zai Lab, Ltd. ("Zai Lab") (Nasdaq: ZLAB)(HKEX: 9688) announce new strategic collaboration in Shanghai, China. The companies will collaborate to facilitate the R&D and commercialization of Zai Lab's cancer drugs through business partnerships in clinical trial patient recruitment, central laboratory testing, companion diagnostics development and marketing activities. The announcement was made at the Zai Lab Innovation Summit on October 12th in Shanghai.
Marc Zhao, the co-founder and Chief Operating Officer of Geneseeq delivered a keynote... More